Ellie Merle: Thanks so much.
Operator: All right. Thank you so much. One moment for our next question. Next question is from William Pickering of Bernstein.
William Pickering: Good afternoon. Thanks for taking my question. So on Adipose, you gave a really interesting update at the R&D Day, but you didn’t disclose the target. I was wondering what the next steps on that program are and when we might learn more about it? Thank you.
Chris Anzalone: Yeah. We have not disclosed targets. We are still in the early days a bit with Adipose. We are — we have we have some ideas for our targets, but we are not prepared to show any more data there quite yet. My hope is that, you’ll start to hear more about the clinical plan for Adipose in 2024.
William Pickering: Got it. Thanks. And then on HeFH, it sounds like you’ve become less definitive on the path forward for ANG3 in that indication versus last year. I was wondering, if you could just talk about sort of what aspects of your thinking have evolved? And how sure you are that you will, in fact, take it forward to Phase 3?
Javier San Martin: Yeah. So I think the issue here is whether we can develop the indication of heFH without a full cardiovascular outcome trial. And there is some presidents support there and some other ones. So we are working our way to understand if there is a subpopulation of heFH that can be pushed forward into a regulatory path without the requirement of the cardiovascular outcome trial. So that’s kind of where we are right now.
William Pickering: Got it. Thank you so much.
Operator: Thank you. One moment for our next question. Next question is from Luca Issi from RBC Capital.
Luca Issi: All right. Thanks so much. And again, maybe circling back on RAGE, James or Javier, what are you hoping to see for the initial readout for FeNO? I understand the follow-up will be short, but what levels do you anticipate at baseline? And what kind of reduction are you hoping to see there? Again, just trying to understand what the ability for initial success there? And then maybe, Ken, if I may. I think your prior 10-Q suggested that the bill the facility in Verona, Wisconsin was going to cost 200 million to 260 million. However, the 10-Q today suggested that number has gone up to 260 million 280 million. One, is that correct? And if two, what drove that change? Thanks so much.
Chris Anzalone: Ken, do you want to start that?
Ken Myszkowski: So we have seen certain cost increases as well as about a quarter of a delay in that project. So you will see that, that total cost comes in a bit higher than we had originally estimated. That’s really it.
Javier San Martin: Yes. So Luca, we do have a good point of reference for the FeNO therapeutics effect and that’s the dupilumab and tezepelumab programs in which they saw somewhere between 40% and 48% reduction. I think it’s either going to call which one, but that’s the RAGE that I think we believe will be convincing that the RAGE inhibition, it does work through the IL-13. So that’s the range that we’re seeing. I think the baseline is 20 and…
Chris Anzalone: Greater than…
Javier San Martin: Greater than 20 FeNO, and people with FeNO greater than 200. So it’s the same population very much of those point of reference, if you will, studies, and we expect to see something similar.
Ken Myszkowski: Got it. Thanks so much.
Operator: All right. Thank you. One moment for our last question. This question is from Brendan Smith of TD Cowen.
